Advani Anjali S, Hunger Stephen P, Burnett Alan K
The Cleveland Clinic Lerner College of Medicine and Department of Hematologic Oncology and Blood Disorders, The Cleveland Clinic, Cleveland, OH, USA.
Semin Oncol. 2009 Jun;36(3):213-26. doi: 10.1053/j.seminoncol.2009.03.007.
In many areas of medicine adolescents are regarded as a discrete group with specific therapeutic, psychological, educational, and resource needs. In the treatment of acute leukemia age is a predictor of response. Thus, in acute lymphoblastic leukemia (ALL) there is a clearly poorer treatment outcome after puberty, while in acute myeloid leukaemia (AML), which is more common in older adults, age is a continuous variable with poorer outcomes in each successive decade. Much is known about other prognostic factors and their relative incidence in each age stratum. Although there is some segregation of favorable factors with relative youth, age usually remains an independent factor with respect to prognosis. Adolescents may be included in pediatric or adult-oriented treatment protocols. Here we discuss the outcome of acute leukemia in adolescents and young adults, particularly with respect to whether they respond similarly to children or other adults.
在医学的许多领域,青少年被视为一个具有特定治疗、心理、教育和资源需求的独立群体。在急性白血病的治疗中,年龄是反应的一个预测指标。因此,在急性淋巴细胞白血病(ALL)中,青春期后的治疗结果明显较差,而在急性髓系白血病(AML)中,这种疾病在老年人中更为常见,年龄是一个连续变量,每增加一个十年,预后就越差。关于其他预后因素及其在每个年龄层的相对发生率,我们已经了解很多。尽管有利因素在相对年轻的人群中存在一定程度的集中,但年龄通常仍是一个独立的预后因素。青少年可能被纳入儿科或成人导向的治疗方案。在此,我们讨论青少年和青年急性白血病的治疗结果,特别是他们对儿童或其他成年人的反应是否相似。